Pharmacophore Modeling, Quantitative Structure-Activity Relationship Analysis, and Shape-Complemented in Silico Screening Allow Access to Novel Influenza Neuraminidase Inhibitors

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of Chemical Information and Modeling

• Publication date

  2009-04-02

• Fields of study

  Biology, Medicine, Chemistry, Computer Science

• Identifiers
  DOI 10.1021/ci8003682PMID 19341295
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin.

  2008cited by this paper
• On the interpretation and interpretability of quantitative structure–activity relationship models

  2008cited by this paper
• A Comparison of Field-Based Similarity Searching Methods: CatShape, FBSS, and ROCS

  2008cited by this paper
• Discovery of new MurF inhibitors via pharmacophore modeling and QSAR analysis followed by in-silico screening.

  2008cited by this paper
• Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of new potent hormone sensitive lipase inhibitors.

  2008cited by this paper
• Discovery of new potent human protein tyrosine phosphatase inhibitors via pharmacophore and QSAR analysis followed by in silico screening.

  2007cited by this paper
• CATALYST Pharmacophore Models and Their Utility As Queries for Searching 3D Databases

  2007cited by this paper
• Rational design of transition-state analogues as potent enzyme inhibitors with therapeutic applications.

  2007cited by this paper
• Combining docking, scoring and molecular field analyses to probe influenza neuraminidase-ligand interactions.

  2007cited by this paper
• Pharmacophore Model Generation Software Tools

  2006cited by this paper
• Avian flu to human influenza.

  2006cited by this paper
• Expect the unexpected or caveat for drug designers: multiple structure determinations using aldose reductase crystals treated under varying soaking and co-crystallisation conditions.

  2006cited by this paper
• Virtual ligand screening: strategies, perspectives and limitations

  2006cited by this paper
• Neuraminidase pharmacophore model derived from diverse classes of inhibitors.

  2006cited by this paper
• Roles of neuraminidase in the initial stage of influenza virus infection.

  2006cited by this paper
• Vaccines and Antiviral Drugs in Pandemic Preparedness

  2006cited by this paper
• Unsaturated N-acetyl- D-glucosaminuronic acid glycosides as inhibitors of influenza virus sialidase

  2006cited by this paper
• Avian flu: Isolation of drug-resistant H5N1 virus

  2005cited by this paper
• The Structure, Function, and Inhibition of Influenza Virus Neuraminidase

  2005cited by this paper
• Enzymatic transition states and transition state analogues.

  2005cited by this paper
• The threat of an avian influenza pandemic.

  2005cited by this paper
• Ligand-based assessment of factor Xa binding site flexibility via elaborate pharmacophore exploration and genetic algorithm-based QSAR modeling.

  2005cited by this paper
• Heterogeneity and inaccuracy in protein structures solved by X-ray crystallography.

  2004cited by this paper
• Pruned receptor surface models and pharmacophores for three-dimensional database searching.

  2004cited by this paper
• Influenza Virus Neuraminidase Inhibitors: Generation and Comparison of Structure-Based and Common Feature Pharmacophore Hypotheses and Their Application in Virtual Screening

  2004cited by this paper
• Influenza neuraminidase inhibitors: structure-based design of a novel inhibitor series.

  2003cited by this paper
• Enzymatic transition state poise and transition state analogues.

  2003cited by this paper
• Synthesis and anti-influenza evaluation of orally active bicyclic ether derivatives related to zanamivir.

  2003cited by this paper
• Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI).

  2003cited by this paper
• Non-peptide angiotensin II receptor antagonists: chemical feature based pharmacophore identification.

  2003cited by this paper
• Recent strategies in the search for new anti-influenza therapies.

  2003cited by this paper
• LigandFit: a novel method for the shape-directed rapid docking of ligands to protein active sites.

  2003cited by this paper
• GPCRs: an update on structural approaches to drug discovery

  2003cited by this paper
• Successful shape-Based virtual screening: The discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI)

  2003cited by this paper
• The Importance of Being Earnest: Validation is the Absolute Essential for Successful Application and Interpretation of QSPR Models

  2003cited by this paper
• pH‐Dependent Binding Modes Observed in Trypsin Crystals: Lessons for Structure‐Based Drug Design

  2002cited by this paper
• Why do we need so many chemical similarity search methods?

  2002cited by this paper
• New Millennium Antivirals against Pandemic and Epidemic Influenza: The Neuraminidase Inhibitors

  2002cited by this paper
• Pandemic influenza: its origin and control.

  2002cited by this paper
• Synthesis and anti-influenza virus activity of 4-guanidino-7-substituted Neu5Ac2en derivatives.

  2002cited by this paper
• Synthesis and anti-influenza virus activity of 7-O-alkylated derivatives related to zanamivir.

  2002cited by this paper
• Systematic structure-based design and stereoselective synthesis of novel multisubstituted cyclopentane derivatives with potent antiinfluenza activity.

  2001cited by this paper
• Sialidase inhibitors related to zanamivir. Further SAR studies of 4-amino-4H-pyran-2-carboxylic acid-6-propylamides.

  2001cited by this paper
• Synthesis of (3R*,4R*)-4-acetylamino-3-(pent-3-oxy)cyclohex-1-ene-1-carboxylic acid and its (3S*,4R*)-isomer and their inhibitory action against influenza virus sialidases

  2001cited by this paper
• Carbocyclic influenza neuraminidase inhibitors possessing a C3-cyclic amine side chain: synthesis and inhibitory activity.

  2000cited by this paper
• BCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug design.

  2000cited by this paper
• Synthesis and influenza virus sialidase inhibitory activity of analogues of 4-Guanidino-Neu5Ac2en (Zanamivir) modified in the glycerol side-chain.

  1999cited by this paper
• Potent inhibition of influenza sialidase by a benzoic acid containing a 2-pyrrolidinone substituent.

  1999cited by this paper
• Hydrophobic benzoic acids as inhibitors of influenza neuraminidase.

  1999cited by this paper
• 4-Acetylamino-3-(imidazol-1-yl)-benzoic acids as novel inhibitors of influenza sialidase

  1999cited by this paper
• Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B.

  1998cited by this paper
• A new series of C3-aza carbocyclic influenza neuraminidase inhibitors: synthesis and inhibitory activity.

  1998cited by this paper
• Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides.

  1998cited by this paper
• Structure−Activity Relationship Studies of Novel Carbocyclic Influenza Neuraminidase Inhibitors

  1998cited by this paper
• Sialidase as a target for inhibitors of influenza virus replication.

  1997cited by this paper
• Design and synthesis of benzoic acid derivatives as influenza neuraminidase inhibitors using structure-based drug design.

  1997cited by this paper
• Structure-activity relationships of carbocyclic influenza neuraminidase inhibitors

  1997cited by this paper
• Novel inhibitors of influenza sialidases related to zanamivir. Heterocyclic replacements of the glycerol sidechain

  1997cited by this paper
• Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity.

  1997cited by this paper
• Novel Inhibitors of Influenza Sialidases Related to GG167. Structure- Activity, Crystallographic, and Molecular Dynamics Studies with 4H- Pyran-2-carboxylic Acid 6-Carboxamides.

  1997cited by this paper
• 'Flu' and structure-based drug design.

  1997cited by this paper
• Synthesis and influenza virus sialidase inhibitory activity of analogues of 4-guanidino-Neu5Ac2en (GG167) with modified 5-substituents

  1996cited by this paper
• Poling: Promoting conformational variation

  1995cited by this paper
• Influenza virus neuraminidase: Structure, antibodies, and inhibitors

  1994cited by this paper
• Application of Genetic Function Approximation to Quantitative Structure-Activity Relationships and Quantitative Structure-Property Relationships

  1994cited by this paper
• Rational design of potent sialidase-based inhibitors of influenza virus replication

  1993cited by this paper
• The neuraminidase of influenza virus

  1989cited by this paper
• Structure of the catalytic and antigenic sites in influenza virus neuraminidase

  1983cited by this paper
• Fluorometric assay of neuraminidase with a sodium (4-methylumbelliferyl-alpha-D-N-acetylneuraminate) substrate.

  1979cited by this paper

• Discovery of Novel Natural Inhibitors of H5N1 Neuraminidase Using Integrated Molecular Modeling and ADMET Prediction

  2025cites this paper
• Pharmacophore modeling, 2D-QSAR, Molecular Docking and ADME studies for the discovery of inhibitors of PBP2a in MRSA

  2025cites this paper
• Ligand-based pharmacophore modeling and machine learning for the discovery of potent aurora A kinase inhibitory leads of novel chemotypes

  2024cites this paper
• SmartCADD: AI-QM Empowered Drug Discovery Platform with Explainability

  2024cites this paper
• Augmenting bioactivity by docking‐generated multiple ligand poses to enhance machine learning and pharmacophore modelling: discovery of new TTK inhibitors as case study

  2023cites this paper
• Palladium-Catalyzed Hydroalkoxycarbonylation and Hydroxycarbonylation of Cyclopent-3-en-1-ols: Divergent Synthesis of Bridged Cyclic Lactones and β,γ-Unsaturated Carboxylic Acids.

  2023cites this paper
• Development of phosphoinositide 3-kinase delta (PI3Kδ) inhibitors as potential anticancer agents through the generation of ligand-based pharmacophores and biological screening

  2023cites this paper
• Discovery of new Cdc2-like kinase 4 (CLK4) inhibitors via pharmacophore exploration combined with flexible docking-based ligand/receptor contact fingerprints and machine learning

  2022cites this paper
• Ligand-Based Modeling of CXC Chemokine Receptor 4 and Identification of Inhibitors of Novel Chemotypes as Potential Leads towards New Anti-COVID-19 Treatments.

  2022cites this paper
• Exploiting activity cliffs for building pharmacophore models and comparison with other pharmacophore generation methods: sphingosine kinase 1 as case study

  2022cites this paper
• QSAR-guided pharmacophoric modeling reveals important structural requirements for Polo kinase 1 (Plk1) inhibitors.

  2021cites this paper
• Pharmacophore modeling of JAK1: A target infested with activity-cliffs.

  2020cites this paper
• Ligand Based Pharmacophore Modeling Followed by Biological Screening Lead to Discovery of Novel PDK1 Inhibitors as Anticancer Agents.

  2019cites this paper
• Discovery of novel Flt3 inhibitory chemotypes through extensive ligand-based and new structure-based pharmacophore modelling methods.

  2019cites this paper
• Pharmacophore modelling, 3D-QSAR and docking study of HIV inhibitor

  2018cites this paper
• Ligand-based computer aided drug design reveals new tropomycin receptor kinase a (TrkA) inhibitors.

  2018cites this paper
• Ligand-based modeling of Akt3 lead to potent dual Akt1/Akt3 inhibitor.

  2018cites this paper
• Computational modeling of the bat HKU4 coronavirus 3CLpro inhibitors as a tool for the development of antivirals against the emerging Middle East respiratory syndrome (MERS) coronavirus

  2017cites this paper
• Discovery of novel potent nuclear factor kappa‐B inhibitors (IKK‐β) via extensive ligand‐based modeling and virtual screening

  2017cites this paper
• Computer-aided discovery of new FGFR-1 inhibitors followed by in vitro validation.

  2016cites this paper
• The in Silico Study of Nutmeg Seeds (Myristica fragrans Houtt) as Peroxisome Proliferator Activated Receptor Gamma Activator Using 3D-QSAR Pharmacophore Modelling

  2016cites this paper
• Ligand-based modeling of diverse aryalkylamines yields new potent P-glycoprotein inhibitors.

  2016cites this paper
• Innovative computer-aided methods for the discovery of new kinase ligands.

  2016cites this paper
• Discovery of new selective cytotoxic agents against Bcl-2 expressing cancer cells using ligand-based modeling.

  2016cites this paper
• Discovery of Check Point Kinase 1 (Chk1) Inhibitors as Potential Anticancer Agents Using Ligand-Based Modelling and Virtual Screening

  2015cites this paper
• Ligand-based modeling followed by in vitro bioassay yielded new potent glucokinase activators.

  2015cites this paper
• Identification of novel inhibitors for Pim-1 kinase using pharmacophore modeling based on a novel method for selecting pharmacophore generation subsets

  2015cites this paper
• QSAR Study of H1N1 Neuraminidase Inhibitors from Influenza a Virus

  2014cites this paper
• Development of 3D-QSAR combination approach for discovering and analysing neuraminidase inhibitors in silico

  2014cites this paper
• Elaborate ligand-based modeling reveals new human neutrophil elastase inhibitors

  2014cites this paper
• Advances in quantitative structure–activity relationship models of anti-Alzheimer’s agents

  2014cites this paper
• Discovery of novel urokinase plasminogen activator (uPA) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis

  2014cites this paper
• Discovery of nanomolar phosphoinositide 3-kinase gamma (PI3Kγ) inhibitors using ligand-based modeling and virtual screening followed by in vitro analysis.

  2014cites this paper
• Receptor-based pharmacophore tool for design and development of next-generation drugs

  2013cites this paper
• Ligand-based pharmacophore exploration and QSAR analysis of transition state analogues followed by in silico screening guide the discovery of new sub-micromolar β-secreatase inhibitors

  2013cites this paper
• Elaborate ligand-based modeling reveal new migration inhibitory factor inhibitors.

  2013cites this paper
• Elaborate ligand-based modeling coupled with QSAR analysis and in silico screening reveal new potent acetylcholinesterase inhibitors

  2013cites this paper
• Recent advances in the structure-based design of neuraminidase inhibitors as antiinfluenza agents.

  2012cites this paper
• EVALUATION OF ANTI-INFLUENZA ACTIVITY OF CURCUMIN DERIVATIVES BY DOCKING AND PHARMACOPHORE MODELING APPROACH

  2012cites this paper
• Pharmacophore and QSAR Modeling of Endothelial Nitric Oxide Synthase Inhibitors and Subsequent Validation and In Silico Search for New Hits

  2012cites this paper
• Extensive ligand-based modeling and in silico screening reveal nanomolar inducible nitric oxide synthase (iNOS) inhibitors.

  2012cites this paper
• A simple synthesis of N-perfluoroacylated and N-acylated glycals of neuraminic acid with a cyclic aminic substituent at the 4α position as possible inhibitors of sialidases.

  2012cites this paper
• Memory CD4+ T Cells: fate determination, positive feedback and plasticity

  2012cites this paper
• Influenza neuraminidase: a druggable target for natural products.

  2012cites this paper
• Elaborate ligand-based modeling reveal new submicromolar Rho kinase inhibitors

  2012cites this paper
• Molecular modeling, docking and ADMET studies towards development of novel Disopyramide analogs for potential inhibition of human voltage gated sodium channel proteins

  2012cites this paper
• PHARMACOPHORE MODELLING, DOCKING AND BIOLOGICAL EVALUATION OF VANILLIN DERIVATIVES AS NEURAMINIDASE INHIBITORS

  2012cites this paper
• Discovery of new β‐D‐galactosidase inhibitors via pharmacophore modeling and QSAR analysis followed by in silico screening

  2011cites this paper
• Pharmacophore Models for Virtual Screening

  2011cites this paper
• Identifying factors controlling protein release from combinatorial biomaterial libraries via hybrid data mining methods.

  2011cites this paper
• Discovery of new β-d-glucosidase inhibitors via pharmacophore modeling and QSAR analysis followed by in silico screening

  2011cites this paper
• Pharmacophore-based virtual screening.

  2011cites this paper
• Discovery of new nanomolar peroxisome proliferator-activated receptor γ activators via elaborate ligand-based modeling.

  2011cites this paper
• Discovery of new renin inhibitory leads via sequential pharmacophore modeling, QSAR analysis, in silico screening and in vitro evaluation.

  2011cites this paper
• Development of Novel 3D-QSAR Combination Approach for Screening and Optimizing B-Raf Inhibitors in silico

  2011cites this paper
• Discovery of New Antifungal Leads via Pharmacophore Modeling and QSAR Analysis of Fungal N‐Myristoyl Transferase Inhibitors Followed by In Silico Screening

  2011cites this paper
• Covariance matrix self-adaptation evolution strategies and other metaheuristic techniques for neural adaptive learning

  2011cites this paper
• Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration.

  2010influential citation
• Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay.

  2010cites this paper
• Elaborate Ligand-Based Modeling Reveals New Nanomolar Heat Shock Protein 90α Inhibitors

  2010cites this paper
• Develop integration modeling approach for discovery neuraminidase inhibitors in silico based on pharmacophore and CoMSIA models

  2010cites this paper
• Elaborate ligand-based pharmacophore exploration and QSAR analysis guide the synthesis of novel pyridinium-based potent beta-secretase inhibitory leads.

  2010cites this paper
• Correlation Analyses on Binding Affinity of Sialic Acid Analogues with Influenza Virus Neuraminidase-1 Using ab Initio MO Calculations on Their Complex Structures

  2010cites this paper
• Pharmacophore Modeling of N 1-alkyltheobromine as Histamine-H 1 Receptor Antagonist

  year unknowncites this paper